Ertapenem as initial antimicrobial monotherapy for patients with chronic obstructive pulmonary disease hospitalized with typical community-acquired pneumonia

Pulmonary Pharmacology and Therapeutics

Volumn 17, Issue 4, 2004, Pages 199-203

  Friedland, Ian R ^a   McCarroll, Kathleen A ^a   DiNubile, Mark J ^a,b   Woods, Gail L ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

^b NONE   (United States)

Author keywords

Ceftriaxone; Chronic obstructive pulmonary disease; Community acquired pneumonia; Ertapenem

Indexed keywords

CEFTRIAXONE; ERTAPENEM;

ADULT; AGED; ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL FEATURE; CLINICAL TRIAL; COMMUNITY ACQUIRED PNEUMONIA; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEMOGRAPHY; DISEASE SEVERITY; FEMALE; HAEMOPHILUS INFLUENZAE; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; POPULATION RESEARCH; PRIORITY JOURNAL; RISK ASSESSMENT; STREPTOCOCCUS PNEUMONIAE; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; BETA-LACTAMS; CEFTRIAXONE; COMMUNITY-ACQUIRED INFECTIONS; DRUG THERAPY, COMBINATION; ENTEROBACTERIACEAE; FEMALE; HAEMOPHILUS INFLUENZAE; HOSPITALIZATION; HUMANS; INJECTIONS, INTRAVENOUS; LACTAMS; MALE; MIDDLE AGED; PNEUMONIA, BACTERIAL; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RANDOMIZED CONTROLLED TRIALS; STREPTOCOCCUS PNEUMONIAE; TREATMENT OUTCOME;

EID: 3042667214     PISSN: 10945539     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pupt.2004.03.002     Document Type: Article

References (12)

1. Centers for Disease Control and Prevention. Premature deaths, monthly mortality and monthly physician contacts: United States. MMWR Morb Mortal Wkly Rep. 46:1997;566
2. Barnes P.J. Chronic obstructive pulmonary disease. N Engl J Med. 343:2000;269-280
3. Fuchs P.C., Barry A.L., Brown S.D. In vitro activities of ertapenem (MK-0826) against clinical bacterial isolates from 11 North American medical centers. Antimicrob Agents Chemother. 45:2001;1915-1918
4. Friedland I., Isaacs R., Mixson L.A., Motyl M., Woods G.L. Use of surrogate antimicrobial agents to predict susceptibility to ertapenem. Diagn Microbiol Infect Dis. 43:2002;61-64
5. Livermore D.M., Carter M.W., Bagel S., et al. In vitro activities of ertapenem (MK-0826) against recent clinical bacteria collected in Europe and Australia. Antimicrob Agents Chemother. 45:2001;1860-1867
6. Ortiz-Ruiz G., Caballero-Lopez J., Friedland I., Woods G.L., Carides A. and the Protocol 018 Ertapenem Community-Acquired Pneumonia Study Group. A study evaluating the efficacy, safety, and tolerability of ertapenem versus ceftriaxone for the treatment of community-acquired pneumonia in adults. Clin Infect Dis. 34:2002;1076-1083
7. Vetter N., Cambronero-Hernandez E., Rohlf J., et al. A prospective, randomized, double-blind multicenter comparison of parenteral ertapenem and ceftriaxone for treatment of hospitalized adults with community-acquired pneumonia. Clin Therapeutics. 24:2002;1770-1785
8. Beam T.R. Jr, Gilbert D.N., Kunin C.M. General guidelines for the clinical evaluation of anti-infective drug products. Clin Infect Dis. 15:(1):1992;S5-32
9. Fine M.J., Auble T.E., Yealy D.M., et al. A prediction rule to identify low-risk patients with community acquired pneumonia. N Engl J Med. 336:1997;243-250
10. National Committee for Clinical Laboratory Standards. Performance standards for antimicrobial disk susceptibility tests: approved standard. NCCLS document M2-A6. 1997;National Committee for Clinical Laboratory Standards, Wayne, PA
11. National Committee for Clinical Laboratory Standards. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically: approved standard. NCCLS document M7-A5. 2000;National Committee for Clinical Laboratory Standards, Wayne, PA
12. Torres A., Dorca J., Zalacain R., et al. Community-acquired pneumonia in chronic obstructive pulmonary disease. A Spanish multicenter study. Am J Respir Crit Care Med. 154:1996;1456-1461